124 related articles for article (PubMed ID: 25228978)
1. Validation of group B borderline resectable pancreatic cancer: retrospective analysis.
Oh TG; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Seong J; Kang CM; Lee WJ; Park JY
Gut Liver; 2014 Sep; 8(5):557-62. PubMed ID: 25228978
[TBL] [Abstract][Full Text] [Related]
2. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
[TBL] [Abstract][Full Text] [Related]
3. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Katz MH; Pisters PW; Evans DB; Sun CC; Lee JE; Fleming JB; Vauthey JN; Abdalla EK; Crane CH; Wolff RA; Varadhachary GR; Hwang RF
J Am Coll Surg; 2008 May; 206(5):833-46; discussion 846-8. PubMed ID: 18471707
[TBL] [Abstract][Full Text] [Related]
4. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
5. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
[TBL] [Abstract][Full Text] [Related]
6. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
[TBL] [Abstract][Full Text] [Related]
7. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
8. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
9. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
10. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
11. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
Takahashi H; Akita H; Tomokuni A; Kobayashi S; Ohigashi H; Fijiwara Y; Yano M; Sakon M; Ishikawa O
Ann Surg; 2016 Dec; 264(6):1091-1097. PubMed ID: 27462960
[TBL] [Abstract][Full Text] [Related]
13. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
[TBL] [Abstract][Full Text] [Related]
15. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
17. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; Yu J; Borel Rinkes IHM; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Eur J Surg Oncol; 2019 Sep; 45(9):1674-1683. PubMed ID: 31023560
[TBL] [Abstract][Full Text] [Related]
18. Self-expanding metal stents (SEMS) for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer: outcomes in 241 patients.
Siddiqui AA; Mehendiratta V; Loren D; Kowalski T; Fang J; Hilden K; Adler DG
Dig Dis Sci; 2013 Jun; 58(6):1744-50. PubMed ID: 23179157
[TBL] [Abstract][Full Text] [Related]
19. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study.
Jang JY; Kang JS; Han Y; Heo JS; Choi SH; Choi DW; Park SJ; Han SS; Yoon DS; Park JS; Yu HC; Kang KJ; Kim SG; Lee H; Kwon W; Yoon YS; Han HS; Kim SW
J Hepatobiliary Pancreat Sci; 2017 Jul; 24(7):426-433. PubMed ID: 28514000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
